Nippon Flour Mills Co., Ltd., Central Laboratory, Midorigaoka, Atsugi, Kanagawa, Japan.
Nutr Res. 2010 Jul;30(7):441-6. doi: 10.1016/j.nutres.2010.06.004.
The effects of flaxseed lignan (secoisolariciresinol diglucoside [SDG]) intake on hypercholesterolemia and liver disease risk factors in moderately hypercholesterolemic men were investigated. In a previous study, we reported that SDG attenuates high-fat, diet-induced hypercholesterolemia in mice. Here, we report a double-blinded, randomized, and placebo-controlled study in moderately hypercholesterolemic men in which we investigated the hypothesis that oral administration of SDG (20 or 100 mg) would decrease the level of blood cholesterol and liver disease risk factors induced by hypercholesterolemia in humans. Thirty men with total cholesterol levels of 4.65 to 6.21 mmol/L (180-240 mg/dL) were randomly assigned to 3 groups; 2 groups received flaxseed lignan capsules (SDG, 20 or 100 mg/d) and the other received placebo capsules for 12 weeks. We found that, compared to the subjects who received placebo, those who received 100 mg of SDG exhibited a significant reduction in the ratio of low-density lipoprotein/high-density lipoprotein cholesterol at baseline (P < .05) and at week 12 (P < .05). In addition, in SDG-treated subjects, we also observed a significant percentage decrease in the levels of glutamic pyruvic transaminase and gamma-glutamyl transpeptidase relative to the levels at baseline (P < .01) and a significant percentage decrease in the level of gamma-glutamyl transpeptidase relative to the placebo-treated group (P < .05). These results suggest that daily administration of 100 mg SDG can be effective at reducing blood level of cholesterol and hepatic diseases risk in moderately hypercholesterolemic men.
我们研究了亚麻籽木脂素（开环异落叶松脂素二葡萄糖苷[SDG]）摄入对中度高胆固醇血症男性的高胆固醇血症和肝病危险因素的影响。在之前的一项研究中，我们报告 SDG 可减轻高脂肪饮食诱导的小鼠高胆固醇血症。在这里，我们报告了一项在中度高胆固醇血症男性中进行的双盲、随机、安慰剂对照研究，我们假设口服 SDG（20 或 100mg）可降低由高胆固醇血症引起的血液胆固醇和肝病危险因素的水平。30 名总胆固醇水平为 4.65 至 6.21mmol/L（180-240mg/dL）的男性被随机分为 3 组；2 组接受亚麻籽木脂素胶囊（SDG，20 或 100mg/d），另 1 组接受安慰剂胶囊，持续 12 周。我们发现，与接受安慰剂的受试者相比，接受 100mg SDG 的受试者在基线时（P<0.05）和第 12 周时（P<0.05）的低密度脂蛋白/高密度脂蛋白胆固醇比值显著降低。此外，在 SDG 治疗的受试者中，我们还观察到谷氨酰丙酮酸转氨酶和γ-谷氨酰转肽酶的水平相对于基线水平有显著的百分比下降（P<0.01），以及相对于安慰剂治疗组，γ-谷氨酰转肽酶的水平有显著的百分比下降（P<0.05）。这些结果表明，每天服用 100mg SDG 可有效降低中度高胆固醇血症男性的血液胆固醇水平和肝脏疾病风险。
